Amivantamab binds EGFR on target cells and its IgG1 Fc engages FcγR-bearing effector cells (e.g., NK cells, macrophages) to mediate ADCC and ADCP, killing EGFR-expressing cells; it also blocks signaling/internalizes receptors (antiproliferative).